LACK OF CLINICAL BENEFIT FROM SUBCUTANEOUS TUNNEL INSERTION OF CENTRAL VENOUS CATHETERS IN IMMUNOCOMPROMISED PATIENTS

To assess the efficacy of subcutaneous tunneling, we randomly designat ed 212 central venous catheters for tunneling (107 catheters) or for s tandard insertion (105 catheters) in 169 immunocompromised patients. T he patients who received tunneled catheters (TCs) and the patients who received nontunneled catheters (NTCs) were similar with respect to ag e, gender, underlying disease, incidence of leukopenic episodes, recei pt of blood product transfusions or parenteral nutrition, and medical care and attendants. The life span of catheters was 112.5 +/- 9.5 days in the TC group and 119 +/- 9 days in the NTC group (P = .5). Clinica lly relevant bacteremia occurred in 26 cases in the TC group (0.22 epi sode per 100 catheter-days), a rate not significantly different from t hat in the NTC group (25 episodes; 0.20 episode per 100 catheter-days) . Catheter-related bacteremia was documented in seven cases and non-ca theter-related bacteremia in five cases. In most instances, the precis e origin of the septic episode could not be determined. Cutaneous infe ction and bacteremia were associated with the same microorganism in tw o cases in each group. Since the present study failed to demonstrate a ny clinical benefit of subcutaneous tunneling, such a procedure is no longer performed in our hospital.